Cooper Companies Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Cooper Companies wird ein jährliches Gewinn- und Umsatzwachstum von 23% bzw. 7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10% betragen.
Wichtige Informationen
23.0%
Wachstumsrate der Gewinne
24.1%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 7.0% |
| Zukünftige Eigenkapitalrendite | 10.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 14 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
The Cooper Companies: Winning Share In Contact Lens Markets
Oct 09Are Investors Undervaluing The Cooper Companies, Inc. (NASDAQ:COO) By 35%?
Oct 01
Returns On Capital At Cooper Companies (NASDAQ:COO) Paint A Concerning Picture
Sep 15The Cooper Companies: Still An Expensive Place
Aug 26Investors Interested In The Cooper Companies, Inc.'s (NASDAQ:COO) Earnings
Aug 17Is There Now An Opportunity In The Cooper Companies, Inc. (NASDAQ:COO)?
Jul 30Is There An Opportunity With The Cooper Companies, Inc.'s (NASDAQ:COO) 36% Undervaluation?
Jun 20Cooper Companies: Business Growth Noted, Valuations An Ask
Jun 14Investors Could Be Concerned With Cooper Companies' (NASDAQ:COO) Returns On Capital
May 21With The Cooper Companies, Inc. (NASDAQ:COO) It Looks Like You'll Get What You Pay For
May 02Should You Think About Buying The Cooper Companies, Inc. (NASDAQ:COO) Now?
Apr 17The Cooper Companies: Rating Upgrade As Near-Term Momentum Should Continue
Mar 22Calculating The Intrinsic Value Of The Cooper Companies, Inc. (NASDAQ:COO)
Mar 18The Cooper Companies: I Still Don't See Much Upside
Mar 01These 4 Measures Indicate That Cooper Companies (NASDAQ:COO) Is Using Debt Reasonably Well
Jan 23Cooper Companies: Women Health Business Makes Room For Growth; Path For Margin Expansion
Jan 15When Should You Buy The Cooper Companies, Inc. (NASDAQ:COO)?
Jan 08With The Cooper Companies, Inc. (NASDAQ:COO) It Looks Like You'll Get What You Pay For
Dec 24A Look At The Fair Value Of The Cooper Companies, Inc. (NASDAQ:COO)
Nov 30Investors Could Be Concerned With Cooper Companies' (NASDAQ:COO) Returns On Capital
Oct 30What Does The Cooper Companies, Inc.'s (NASDAQ:COO) Share Price Indicate?
Sep 28Cooper Offers A Great Business But A Somewhat Tricky Valuation
Sep 25Here's Why Cooper Companies (NYSE:COO) Can Manage Its Debt Responsibly
Sep 10Calculating The Fair Value Of The Cooper Companies, Inc. (NYSE:COO)
Aug 23Cooper Companies (NYSE:COO) Is Reinvesting At Lower Rates Of Return
Jul 24The Cooper Companies: Valuation Is Too High (Rating Downgrade)
Jul 12When Should You Buy The Cooper Companies, Inc. (NYSE:COO)?
Jun 24Is Cooper Companies (NYSE:COO) Using Too Much Debt?
Jun 08Estimating The Intrinsic Value Of The Cooper Companies, Inc. (NYSE:COO)
May 24Investors Could Be Concerned With Cooper Companies' (NYSE:COO) Returns On Capital
Apr 23At US$355, Is The Cooper Companies, Inc. (NYSE:COO) Worth Looking At Closely?
Mar 25These 4 Measures Indicate That Cooper Companies (NYSE:COO) Is Using Debt Reasonably Well
Feb 04Cooper Companies: Growth Comes At A High Cost To Equity Holders, Rate Hold
Jan 30Estimating The Fair Value Of The Cooper Companies, Inc. (NYSE:COO)
Jan 19Investors Could Be Concerned With Cooper Companies' (NYSE:COO) Returns On Capital
Jan 04Cooper Cos. initiated at buy at Mizuho on contact lenses, cataract implants positioning
Dec 22Is It Too Late To Consider Buying The Cooper Companies, Inc. (NYSE:COO)?
Dec 20The Cooper Companies declares $0.03 dividend
Dec 14The Cooper Companies Non-GAAP EPS of $2.75 misses by $0.36, revenue of $848.1M beats by $9.22M
Dec 08Cooper Companies: Questions On Viability Of Future Earnings Upside
Nov 04Are Investors Undervaluing The Cooper Companies, Inc. (NYSE:COO) By 38%?
Oct 18BioSkryb, Cooper ink license deal for genomic technology for women's reproductive health
Oct 18Be Wary Of Cooper Companies (NYSE:COO) And Its Returns On Capital
Oct 03Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 10/31/2027 | 4,907 | 882 | 1,012 | 1,429 | 2 |
| 10/31/2026 | 4,473 | 778 | 703 | 1,051 | 13 |
| 10/31/2025 | 4,201 | 645 | 626 | 944 | 18 |
| 10/31/2024 | 3,903 | 447 | 541 | 816 | 17 |
| 7/31/2024 | 3,804 | 359 | 189 | 615 | N/A |
| 4/30/2024 | 3,732 | 340 | 122 | 550 | N/A |
| 1/31/2024 | 3,666 | 291 | 136 | 564 | N/A |
| 10/31/2023 | 3,593 | 294 | 215 | 608 | N/A |
| 7/31/2023 | 3,514 | 275 | 222 | 564 | N/A |
| 4/30/2023 | 3,427 | 288 | 387 | 685 | N/A |
| 1/31/2023 | 3,380 | 375 | 425 | 693 | N/A |
| 10/31/2022 | 3,308 | 386 | 450 | 692 | N/A |
| 7/31/2022 | 3,219 | 431 | 524 | 736 | N/A |
| 4/30/2022 | 3,139 | 948 | 487 | 696 | N/A |
| 1/31/2022 | 3,029 | 939 | 541 | 757 | N/A |
| 10/31/2021 | 2,923 | 2,945 | 524 | 739 | N/A |
| 7/31/2021 | 2,845 | 2,916 | 526 | 782 | N/A |
| 4/30/2021 | 2,660 | 2,355 | 414 | 671 | N/A |
| 1/31/2021 | 2,465 | 2,249 | 207 | 505 | N/A |
| 10/31/2020 | 2,431 | 238 | 176 | 487 | N/A |
| 7/31/2020 | 2,441 | 278 | 180 | 468 | N/A |
| 4/30/2020 | 2,542 | 343 | 234 | 552 | N/A |
| 1/31/2020 | 2,672 | 454 | 459 | 741 | N/A |
| 10/31/2019 | 2,653 | 467 | 421 | 713 | N/A |
| 7/31/2019 | 2,613 | 446 | 499 | 750 | N/A |
| 4/30/2019 | 2,594 | 427 | 561 | 788 | N/A |
| 1/31/2019 | 2,571 | 366 | 523 | 745 | N/A |
| 10/31/2018 | 2,533 | 140 | -630 | 669 | N/A |
| 7/31/2018 | 2,443 | 128 | -656 | 631 | N/A |
| 4/30/2018 | 2,339 | 131 | N/A | 551 | N/A |
| 1/31/2018 | 2,230 | 175 | N/A | 511 | N/A |
| 10/31/2017 | 2,139 | 373 | N/A | 594 | N/A |
| 7/31/2017 | 2,096 | 345 | N/A | 588 | N/A |
| 4/30/2017 | 2,055 | 329 | N/A | 562 | N/A |
| 1/31/2017 | 2,016 | 298 | N/A | 529 | N/A |
| 10/31/2016 | 1,967 | 274 | N/A | 510 | N/A |
| 7/31/2016 | 1,904 | 250 | N/A | 421 | N/A |
| 4/30/2016 | 1,851 | 207 | N/A | 388 | N/A |
| 1/31/2016 | 1,801 | 194 | N/A | 401 | N/A |
| 10/31/2015 | 1,797 | 204 | N/A | 391 | N/A |
| 7/31/2015 | 1,810 | 198 | N/A | 439 | N/A |
| 4/30/2015 | 1,780 | 241 | N/A | 450 | N/A |
| 1/31/2015 | 1,758 | 259 | N/A | 466 | N/A |
| 10/31/2014 | 1,718 | 270 | N/A | 455 | N/A |
| 7/31/2014 | 1,661 | 296 | N/A | 453 | N/A |
| 4/30/2014 | 1,640 | 297 | N/A | 448 | N/A |
| 1/31/2014 | 1,611 | 293 | N/A | 437 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: COODas prognostizierte Gewinnwachstum (23% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: COODie Erträge des Unternehmens (23% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: COOEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: COODie Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: COODie Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: COODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10%).